Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody persistence at 5 years after Infanrix hexa or Infanrix-IPV/Hib primary series
2011-000943-26Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pertussis filamentous haemagglutinin and diphtheria + tetanus + acellular pertussis + inactivated poliomyelitis + Haemophilus influenzae type b vaccine in diphtheria, Tetanus, pertussis and 3 more (2 cohorts), sponsored by GSK. Primary endpoint: Primary immunogenicity endpoint. Started Apr 2011; status: completed.
02
Drugs
pertussis filamentous haemagglutinindiphtheria + tetanus + acellular pertussis + inactivated poliomyelitis + Haemophilus influenzae type b vaccine
03
Conditions
diphtheriaTetanuspertussispoliomyelitishepatitis B (HBV)
Beyond the preview
Go deeper on 2011-000943-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000943-26.